EUVIMEDEUVIMED entdecken
Open Access

CD8 + T cell targeting of tumor antigens presented by HLA-E

Ravi F Iyer iD, Marieke C Verweij iD, Sujit S Nair iD, David Morrow iD, Mandana Mansouri iD, Dimple Chakravarty iD, Teresa Beechwood iD, Christine Meyer iD, Luke Uebelhoer, Elvin J Lauron, Andrea Selseth iD, Nessy John iD und 12 weitere

Science Advances · 2024

DOI: 10.1126/sciadv.adm7515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Ravi F Iyer und 23 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, CD8-Positive T-Lymphocytes, HLA-E Antigens. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nonpolymorphic major histocompatibility complex E (MHC-E) molecule is up-regulated on many cancer cells, thus contributing to immune evasion by engaging inhibitory NKG2A/CD94 receptors on NK cells and tumor-infiltrating T cells. To investigate whether MHC-E expression by cancer cells can be targeted for MHC-E–restricted T cell control, we immunized rhesus macaques (RM) with rhesus cytomegalovirus (RhCMV) vectors genetically programmed to elicit MHC-E–restricted CD8 + T cells and to express established tumor-associated antigens (TAAs) including prostatic acidic phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin. T cell responses to all three tumor antigens were comparable to viral antigen-specific responses with respect to frequency, duration, phenotype, epitope density, and MHC restriction. Thus, CMV-vectored cancer vaccines can bypass central tolerance by eliciting T cells to noncanonical epitopes. We further demonstrate that PAP-specific, MHC-E–restricted CD8 + T cells from RhCMV/PAP-immunized RM respond to PAP-expressing HLA-E + prostate cancer cells, suggesting that the HLA-E/NKG2A immune checkpoint can be exploited for CD8 + T cell–based immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmCD8-Positive T-LymphocytesHLA-E AntigensAnimalsHumansMaleAcid PhosphataseAntigen PresentationCancer VaccinesCell Line, TumorCytomegalovirusHistocompatibility Antigens Class IMacaca mulattaMesothelin

Substanzen

Acid PhosphataseAntigens, NeoplasmCancer VaccinesHistocompatibility Antigens Class IHLA-E AntigensMesothelinprostatic acid phosphatase

Autor:innen und Institutionen

  • Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.
  • Department of Urology and Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai, New York, NY 10029, USA.
  • Vir Biotechnology, San Francisco, CA 14158, USA.
  • Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

ORCID-Profile: Ravi F Iyer, Marieke C Verweij, Sujit S Nair, David Morrow, Mandana Mansouri, Dimple Chakravarty, Teresa Beechwood, Christine Meyer, Andrea Selseth, Nessy John, Tin Htwe Thin, Colin Havenar-Daughton, Michael K Axthelm, Alan Korman, Nina Bhardwaj, Ashutosh K Tewari, Scott Hansen, Daniel Malouli, Louis J Picker, Klaus Früh

Förderung

  • NIAID NIH HHS
  • NIH HHS

Zitieren

APA

Iyer, R. F., Verweij, M. C., Nair, S. S., Morrow, D., Mansouri, M., Chakravarty, D., Beechwood, T., Meyer, C., Uebelhoer, L., Lauron, E. J., Selseth, A., John, N., Thin, T. H., Dzedzik, S., Havenar-Daughton, C., Axthelm, M. K., Douglas, J., Korman, A., Bhardwaj, N., …, & Früh, K. (2024). CD8 + T cell targeting of tumor antigens presented by HLA-E. Science Advances. https://doi.org/10.1126/sciadv.adm7515

Vancouver

Iyer RF, Verweij MC, Nair SS, Morrow D, Mansouri M, Chakravarty D, et al. CD8 + T cell targeting of tumor antigens presented by HLA-E. Science Advances. 2024. doi:10.1126/sciadv.adm7515

BibTeX
@article{Iyer2024,
  author = {Iyer, Ravi F and Verweij, Marieke C and Nair, Sujit S and Morrow, David and Mansouri, Mandana and Chakravarty, Dimple and Beechwood, Teresa and Meyer, Christine and Uebelhoer, Luke and Lauron, Elvin J and Selseth, Andrea and John, Nessy and Thin, Tin Htwe and Dzedzik, Siarhei and Havenar-Daughton, Colin and Axthelm, Michael K and Douglas, Janet and Korman, Alan and Bhardwaj, Nina and Tewari, Ashutosh K and Hansen, Scott and Malouli, Daniel and Picker, Louis J and Früh, Klaus},
  title = {CD8 + T cell targeting of tumor antigens presented by HLA-E},
  journal = {Science Advances},
  year = {2024},
  doi = {10.1126/sciadv.adm7515}
}
Kostenlos starten →